结直肠癌个体的癌症易感基因突变
研究招募1058例未按年龄、家族史或MSI/MMR结果预选的结直肠癌患者,进行25个遗传性癌症风险基因的胚系检测,发现9.9%携带至少一个致病突变,其中Lynch综合征占3.1%,非Lynch综合征基因突变占7.0%,MSI/MMR检测可可靠识别Lynch综合征先证者。
要点
- 1058例未预选的结直肠癌患者中,9.9%携带至少一个癌症易感基因致病突变,3.1%为Lynch综合征。
- 7.0%携带非Lynch综合征基因突变,其中2.2%为高外显率基因突变,3.6%为中等外显率基因突变。
- MSI/MMR检测可可靠识别Lynch综合征先证者,但非Lynch综合征突变占比亦较高。
核心结论
- 9.9%的结直肠癌患者携带胚系癌症易感基因突变。
- MSI/MMR检测可可靠识别Lynch综合征先证者,但7.0%的患者携带非Lynch综合征突变,包括1.0%携带BRCA1/2突变。
研究设计与样本
- 研究招募了1058名在诊所接受结直肠癌诊疗的参与者,未对诊断年龄、个人/家族史或MSI/MMR结果进行预选。
- 所有参与者接受了与遗传性癌症风险相关的25个基因的胚系检测,每个基因根据已发表的致病性胚系突变终生癌症风险估计被分类为高外显率或中等外显率。
主要发现
- 1058名参与者中,105名(9.9%;95% CI,8.2%至11.9%)携带一个或多个致病突变,包括33名(3.1%)Lynch综合征。
- 29例可用的Lynch综合征结直肠癌中,28例(96.6%)显示异常MSI/MMR结果。
- 1058名参与者中,74名(7.0%)携带非Lynch综合征基因突变,包括23名(2.2%)携带高外显率基因突变(5例APC,3例双等位基因MUTYH,11例BRCA1/2,2例PALB2,1例CDKN2A,1例TP53),其中15名缺乏提示其潜在突变的临床病史。
- 38名(3.6%)参与者携带中等外显率结直肠癌风险基因突变(19例单等位基因MUTYH,17例APC*I1307K,2例CHEK2)。
- 先证者结直肠癌诊断年龄、结直肠癌家族史、其他癌症个人史均不能显著预测非Lynch综合征基因致病突变的存在。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Hereditary factors play an important role in colorectal cancer (CRC) risk, yet the prevalence of germline cancer susceptibility gene mutations in patients with CRC unselected for high-risk features (eg, early age at diagnosis, personal/family history of cancer or polyps, tumor microsatellite instability [MSI], mismatch repair [MMR] deficiency) is unknown. Patients and Methods We recruited 1,058 participants who received CRC care in a clinic-based setting without preselection for age at diagnosis, personal/family history, or MSI/MMR results. All participants underwent germline testing for mutations in 25 genes associated with inherited cancer risk. Each gene was categorized as high penetrance or moderate penetrance on the basis of published estimates of the lifetime cancer risks conferred by pathogenic germline mutations in that gene. Results One hundred five (9.9%; 95% CI, 8.2% to 11.9%) of 1,058 participants carried one or more pathogenic mutations, including 33 (3.1%) with Lynch syndrome (LS). Twenty-eight (96.6%) of 29 available LS CRCs demonstrated abnormal MSI/MMR results. Seventy-four (7.0%) of 1,058 participants carried non-LS gene mutations, including 23 (2.2%) with mutations in high-penetrance genes (five APC, three biallelic MUTYH, 11 BRCA1/2, two PALB2, one CDKN2A, and one TP53), 15 of whom lacked clinical histories suggestive of their underlying mutation. Thirty-eight (3.6%) participants had moderate-penetrance CRC risk gene mutations (19 monoallelic MUTYH, 17 APC*I1307K, two CHEK2). Neither proband age at CRC diagnosis, family history of CRC, nor personal history of other cancers significantly predicted the presence of pathogenic mutations in non-LS genes. Conclusion Germline cancer susceptibility gene mutations are carried by 9.9% of patients with CRC. MSI/MMR testing reliably identifies LS probands, although 7.0% of patients with CRC carry non-LS mutations, including 1.0% with BRCA1/2 mutations.
引用
- Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017. PMID: 28135145. doi:10.1200/JCO.2016.71.0012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。